Insider Cluster (2 insiders) ·Filed May 4, 2026

INSM

INSMED Inc
NEUTRAL
Impact 3/10
Horizonweeks Processed4mo ago
Insider cluster: 2 insiders, $1.3M total
Actionable Insight • Neutral

The insider sales are too small to be informative. Focus on the strong Q1 earnings and BRINSUPRI launch trajectory as the primary catalysts. Monitor for any larger insider sales in the coming weeks that could signal a change in sentiment.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
INSM ▼ -26.35% at T+60d
NEUTRAL call ✗ call lost -26.35% · α vs SPY -28.20% · entry $140.01 → $103.12
Entry anchored
May 1, 03:59 PM ET
via exchange tick
T+1d
-0.41%
call -0.41% · α -1.20%
$139.44
settled 5mo ago
T+5d
-25.80%
call -25.80% · α -28.73%
$103.89
settled 5mo ago
T+20d
-24.27%
call -24.27% · α -29.91%
$106.03
settled 4mo ago
T+60d
-26.35%
call -26.35% · α -28.20%
$103.12
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Insmed's CEO and CMO sold a combined $1.27M in stock within a week of a strong Q1 2026 earnings beat (revenue up 230% YoY, EPS beat). The CMO's sale ($1.22M) is a cash-out following option exercises; the CEO's sale ($58K) is routine. At 0.005% of market cap, the total is trivial and likely liquidity-driven, not a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$1.3M
Insiders
2

Key Facts

  • CEO William Lewis sold 433 shares for ~$58K on May 4, 2026.
  • CMO Martina Flammer sold 12,119 shares for ~$1.22M on May 11, 2026, following option exercises.
  • Total cluster value of $1.27M represents ~0.005% of INSM's $25.1B market cap.
  • Q1 2026 revenue of $306M (up 230% YoY) and EPS beat consensus; BRINSUPRI guidance reiterated at ≥$1B.
  • All cross-filing context pairs are AMPLIFIERS, but the dollar amount is too small to warrant escalation.

Financial Impact

Total insider sales of $1.27M, negligible relative to $25.1B market cap.

insider holdings

Risk Factors

  • Insider sales could accelerate if the stock continues to rally post-earnings.
  • Any negative news on BRINSUPRI reimbursement or competition could reverse recent gains.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (28 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-INSM-1778705432876
18 reports for INSM
Performance horizon
86% Hit rate 6 of 7 directional calls best @ T+60▲ +31.86%Mar 30, 2026
Filters
Rows
Reports for INSM — sortable, filterable
TypeNow
Aug 19, 2026
6w ago
Insider Cluster
NEUTRAL ★ 4/10
$130.66 $119.92▼ −8.22%▼ −6.70%$111.12 (−14.95%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 4/10
$126.33 $129.41▲ +2.44%▲ +4.19%$111.12 (−12.04%)
Aug 6, 2026
8w ago
8-K
BULLISH ★ 8/10
$132.55 $126.68▼ −4.43%▼ −5.03%$111.12 (−16.17%)
Jul 24, 2026
10w ago
Institutional Cluster
NEUTRAL ★ 4/10
$106.92 $125.77▲ +17.63%▲ +14.00%$111.12 (+3.93%)
Jul 21, 2026
10w ago
ANALYST-UPGRADE
BULLISH ★ 4/10
$108.62 $128.46▲ +18.27%▲ +15.70%$111.12 (+2.30%)
Jul 16, 2026
11w ago
8-K
BULLISH ★ 6/10
$107.46 $126.33▲ +17.56%▲ +13.94%$111.12 (+3.41%)
Jun 26, 2026
14w ago
Insider Cluster
NEUTRAL ★ 2/10
$104.74 $106.92▲ +2.08%▲ +2.36%$111.12 (+6.09%)
Jun 5, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$94.17 $111.54▲ +18.45%▲ +16.81%$111.12 (+18.00%)
Jun 5, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$94.17 $111.54▲ +18.45%▲ +16.81%$111.12 (+18.00%)
May 15, 2026
19w ago
S-3ASR
NEUTRAL ★ 3/10
$107.15 $95.52▼ −10.85%▼ −12.44%$111.12 (+3.71%)
Showing 10 of 18

US Market Status

Market Closed — Opens Mon (65h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 13, 2026